Po63

Optimizing Prostate Cancer Treatment in Men with Advanced Local disease (OPTiMAL) is a single-arm phase II study targeted towards unfavourable risk patients. As a successor to the largest randomized clinical trial (ASCENDE) comparing low-dose-rate prostate brachytherapy (LDR-PB) boost to external beam radiation therapy (EBRT) boost for prostate cancer (PCa) treatment, this study is designed to continue the use of the LDR-PB boost that resulted in high levels of biochemical progression-free survival (b-PFS) in ASCENDE while also aiming to reduce adverse side effects by lowering the overall dose and also limiting high dose regions to identified sites of disease.

Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Tajwar Abrar Aleef, Ingrid T. Spadinger, Shahed K. Mohammed, Septimiu E. Salcudean, S. Sara Mahdavi, William James Morris, Michael Peacock Source Type: research